Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

MSD publishes new data on Keytruda® (pembrolizumab) in NSCLC and mesothelioma

Jun 3, 2023

MSD announced positive results in two studies evaluating Keytruda®, its anti-PD-1 therapy.   

MSD reported that its Phase 3 KEYNOTE-671 trial evaluating Keytruda® plus chemotherapy before surgery and continued as a single agent after surgery showed reduced risk of disease recurrence, progression or death by 42% versus pre-operative chemotherapy in resectable Stage II, IIIA or IIIB non-small cell lung cancer (NSCLC).  Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) previously announced that, based on these results, the U.S. Food and Drug Administration (FDA) accepted a new supplemental Biologics License Application (sBLA) for Keytruda® for the treatment of these patients in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment, with a target action date of October 16, 2023.  

MSD also reported that its Phase 3 KEYNOTE-483 trial evaluating Keytruda® plus chemotherapy as first-line treatment for patients with unresectable advanced pleural mesothelioma showed significantly improved overall survival chemotherapy alone.